-
Mashup Score: 1Many US rheumatologists fail to follow ACR gout guidelines for urate lowering drug dosage - 2 day(s) ago
Rheumatologists report largely adhering to American College of Rheumatology guidelines for gout management, but show notable divergence with the recommended dosages of urate-lowering therapies, according to survey data. “The management of gout remains suboptimal because of the lack of adherence to treatment recommendations by health care providers, patients’ poor understanding of the
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1Many US rheumatologists fail to follow ACR gout guidelines for urate lowering drug dosage - 2 day(s) ago
Rheumatologists report largely adhering to American College of Rheumatology guidelines for gout management, but show notable divergence with the recommended dosages of urate-lowering therapies, according to survey data. “The management of gout remains suboptimal because of the lack of adherence to treatment recommendations by health care providers, patients’ poor understanding of the
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
💡 A survey of U.S. rheumatologists revealed "discordance" between their practice and @ACRheum #gout guidelines, particularly around treatment dosing regimens "Addressing these gaps could improve the quality of patient care," researchers wrote 👇 https://t.co/UqDClDqxZS
-
-
Mashup Score: 1Gout Flares Common Among US Adults, Often Go Unreported - 10 day(s) ago
Gout flares among adults in the US are significantly underreported.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet-
#Gout flares among adults in the United States are significantly underreported to healthcare providers, with nearly 72% of flares either not reported or pretreated/prevented by patients. https://t.co/MEodpsfjN9
-
-
Mashup Score: 1Colchicine curbs cardiovascular event risk when used with urate-lowering therapy for gout - 11 day(s) ago
Colchicine for gout flare prophylaxis reduces the risk for cardiovascular events among patients initiating urate-lowering therapy, according to data published in The Lancet Rheumatology. “Cardiovascular events have been previously reported to be temporally associated with recent previous gout flares (ie, those within the previous 60 days),” Edoardo Cipolletta, MD, an international
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
💊 #Gout patients taking colchicine with urate-lowering therapy had a weighted hazard ratio of 0.82 (95% CI, 0.69-0.94) for cardiovascular events vs. no colchicine More on the data out of @UniofNottingham ⬇️ https://t.co/Y7Ujoi41fd
-
-
Mashup Score: 0Novel Quality Index Linked to Reduced Hospital Admissions for Gout - 2 month(s) ago
The Urate-Lowering Therapy to Acute Treatment Ratio (ULTrA) was linked to fewer gout-related hospital admissions.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Use of a novel quality index called the Urate-Lowering Therapy to Acute Treatment Ratio (ULTrA) may help improve #gout management and reduce associated hospitalizations. Learn more: https://t.co/Ux70dhpFkf
-
-
Mashup Score: 0SEL-212 Advances Refractory Gout Outcomes with Prolonged Treatment - 2 month(s) ago
Clinically meaningful increases in patient-reported outcomes were identified after 3 doses of SEL-212 and strengthened after 3 additional doses.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Results of two randomized Phase 3 trials identified improvement in patient-reported outcomes after treatment with SEL-212, a novel, monthly, two-component infusion therapy, in adults with refractory #gout. Read more: https://t.co/B8txiI3n1e
-
-
Mashup Score: 3ACR Journals On Air: DECT and Gout Remission - 2 month(s) ago
This week we’re joined by two leading experts in gout remissions, Dr. Nicola Dalbeth and Dr. Dansoa Tabi-Amponsah to explore the exciting advances in gout treatment, with a particular focus on Dual-Energy CT (DECT) imaging and its role in achieving gout remission. We dive into how DECT technology is transforming our ability to visualize urate crystals in joints, its implications for patient care, and the potential it holds for long-term gout management and remission.
Source: sites.libsyn.comCategories: General Medicine News, RheumatologyTweet-
NEW EPISODE! This week, we chat with #gout experts Drs. Nicola Dalbeth & Dansoa Tabi-Amponsah about how dual-energy CT is changing the game for gout remission. LISTEN HERE → https://t.co/Q0HDhJnNCB @ACR_Journals https://t.co/e5Hkn6WN2f
-
-
Mashup Score: 3ACR Journals On Air: DECT and Gout Remission - 2 month(s) ago
This week we’re joined by two leading experts in gout remissions, Dr. Nicola Dalbeth and Dr. Dansoa Tabi-Amponsah to explore the exciting advances in gout treatment, with a particular focus on Dual-Energy CT (DECT) imaging and its role in achieving gout remission. We dive into how DECT technology is transforming our ability to visualize urate crystals in joints, its implications for patient care, and the potential it holds for long-term gout management and remission.
Source: sites.libsyn.comCategories: General Medicine News, RheumatologyTweet-
NEW EPISODE! This week, we chat with #gout experts Drs. Nicola Dalbeth & Dansoa Tabi-Amponsah about how dual-energy CT is changing the game for gout remission. LISTEN HERE → https://t.co/Q0HDhJnNCB @ACR_Journals https://t.co/e5Hkn6WN2f
-
-
Mashup Score: 2ACR Journals On Air: DECT and Gout Remission - 2 month(s) ago
This week we’re joined by two leading experts in gout remissions, Dr. Nicola Dalbeth and Dr. Dansoa Tabi-Amponsah to explore the exciting advances in gout treatment, with a particular focus on Dual-Energy CT (DECT) imaging and its role in achieving gout remission. We dive into how DECT technology is transforming our ability to visualize urate crystals in joints, its implications for patient care, and the potential it holds for long-term gout management and remission.
Source: sites.libsyn.comCategories: General Medicine News, RheumatologyTweet-
NEW EPISODE! This week, we chat with #gout experts Drs. Nicola Dalbeth & Dansoa Tabi-Amponsah about how dual-energy CT is changing the game for gout remission. LISTEN HERE → https://t.co/Q0HDhJnNCB @ACR_Journals https://t.co/e5Hkn6WN2f
-
-
Mashup Score: 2Analysis of Gout Remission Definitions in a Randomized Controlled Trial of Colchicine Prophylaxis for People With Gout Initiating Allopurinol - 3 month(s) ago
Objective To investigate (1) the effect of colchicine prophylaxis on gout remission when commencing urate-lowering therapy (ULT), and (2) illness perceptions of people in remission using 2 definitions of gout remission. Methods Data from a 12-month double-blind placebo-controlled trial of 200 people with gout commencing allopurinol were analyzed. Participants were randomly assigned to prophylaxis with 0.5 mg daily colchicine or placebo for 6 months, followed by 6 months of additional follow-up. Gout remission was assessed using the 2016 preliminary definition or simplified definition without patient-reported outcomes. Illness perceptions were assessed using a gout-specific version of the Brief Illness Perception Questionnaire. Results In the first 6 months, few participants were in remission according to either the 2016 preliminary definition (3% for colchicine and 4% for placebo) or the simplified definition (7% for colchicine and 12% for placebo). In the second 6 months, after study
Source: www.jrheum.orgCategories: General Medicine News, General HCPsTweet-
In an RCT of colchicine vs PBO in #gout for 6 months shows that colchicine prophylaxis when initiating ULT did not increase the odds of achieving gout remission. https://t.co/kgNzw0UUIq https://t.co/ZdBT0Fp9Gx
-
💡 A survey of U.S. rheumatologists revealed "discordance" between their practice and @ACRheum #gout guidelines, particularly around treatment dosing regimens "Addressing these gaps could improve the quality of patient care," researchers wrote 👇 https://t.co/UqDClDqxZS